ZOSYN

Drug PFIZER INC.
Total Payments
$1.8M
Transactions
20
Doctors
1
Companies
3

Payment Trends by Year

Year Amount Transactions Doctors
2024 $1,000 1 0
2023 $4,750 1 0
2020 $1,744 2 0
2019 $542,249 4 0
2018 $757,237 8 0
2017 $484,506 4 1

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $1.8M 18 99.7%
Space rental or facility fees (teaching hospital only) $4,750 1 0.3%
Food and Beverage $18.96 1 0.0%

Payments by Type

Research
$1.8M
18 transactions
General
$4,769
2 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
SAFETY AND EFFECTIVENESS OF PIPERACILLINTAZOBACTAM ZOSYN REGISTERED IN THE TREATMENT OF PEDIATRIC HOSPITAL ACQUIRED PNEUMONIA HAP A RETROSPECTIVE COHORT STUDY PFIZER INC. $1.8M 0

Top Doctors Receiving Payments for ZOSYN

Doctor Specialty Location Total Records
Unknown Philadelphia, PA $1.8M 19
, M.D Emergency Medicine Sumter, SC $18.96 1

About ZOSYN

ZOSYN is a drug associated with $1.8M in payments to 1 healthcare providers, recorded across 20 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..

Payment data is available from 2017 to 2024. In 2024, $1,000 was paid across 1 transactions to 0 doctors.

The most common payment nature for ZOSYN is "Unspecified" ($1.8M, 99.7% of total).

ZOSYN is associated with 1 research study, including "SAFETY AND EFFECTIVENESS OF PIPERACILLINTAZOBACTAM ZOSYN REGISTERED IN THE TREATMENT OF PEDIATRIC HOSPITAL ACQUIRED PNEUMONIA HAP A RETROSPECTIVE COHORT STUDY" ($1.8M).